Oncolytic Herpes Simplex Virus Service

Herpes simplex virus (HSV), a member of the alpha-herpesviruses subfamily, shares many similarities with varicella-zoster virus, pseudorabies virus, and infectious bovine rhinotracheitis virus. There are two HSV species: Herpes Simplex Virus Type I (HSV-1) and Herpes Simplex Virus Type II (HSV-2), both of which can infect humans and cause diseases. HSV-1 is a double-stranded DNA virus that is ubiquitous in the general environment, with approximately 58% of the US population and about 67% of the global population having evidence of exposure to HSV-1 at some point during their lifetime. Currently, lysotype HSV is the first virus to be developed into a recombinant oncolytic viral therapeutic vector, and the first oncolytic virus to fight cancer. As a cytolytic virus, HSV possesses the following features:

(1) HSV replicates quickly in cells and has the capability to infect multiple types of cancer cells;
(2) HSV has a large genome that can be easily modified and be inserted with multiple additional transgenes;
(3) HSV can be prevented with antiviral drugs when the dose starts to impose threat to the patients' lives;
(4) HSV does not integrate into the host genome, thus it is unlikely to be oncogenic;
(5) Modifying the glycoprotein of HSV can improve the targeting of tumor cells.

Dual mechanisms of action for oncolytic herpes simplex viruses (oHSVs) in cancer treatment.

Figure 1. Dual mechanisms of action for oncolytic herpes simplex viruses (oHSVs) in cancer treatment.

QVirus™ platform at Creative Biogene is a world leader in the area of virus engineering and packaging. With the deep knowledge on the genetics and molecular biology of HSV, we can provide oncolytic HSV services for our customer to achieve research and treatment purpose. By genetic engineering and optimization, our oncolytic HSV (oHSV) systems are able to produce high titer viruses allowing high level transgene expression in infected host cells.

Our Capability

  • Development of oHSVs involved initial deletion of a single viral gene and subsequently multiple viral gene deletions and modifications.
  • We have engineered oHSVs to limit transcription and/or translation of an essential viral gene by replacing the viral promoters with tissue- or cancer-specific promoters.
  • Co-transfect of the HSV plasmid and HSV genome into packaging cells.
  • Harvest recombinant viruses and perform virus titration (PFU).

Our QVirus™ Platform commits to developing efficacious oHSV for the customer and enabling wider applications in oncolytic virotherapy of cancers. If you have any special requirements, please feel free to contact us.

1. Russell D, et al. Oncolytic virotherapy using herpes simplex virus: how far have we come?. Oncolytic Virotherapy, 2015:207-.
2. Ma W, et al. Oncolytic herpes simplex virus and immunotherapy. BMC Immunology, 2018, 19(1).

For research use only. Not intended for any clinical use.

Quick Inquiry

Our Platform / Application / Support / About Us / Contact Us

Copyright © Creative Biogene. All Rights Reserved.

  • Tel:
  • Fax:
  • Email: